Hive Blockchain: Canaccord Remains Positive On Outlook

On August 26th, Canaccord Genuity Capital Markets’ raised their 12-month price target on Hive Blockchain (TSXV: HIVE) to US$7.00 from US$5.50 while reiterating their buy rating on the stock. They believe that HIVE continues to execute its plan and believe that the current setup is attractive for many reasons.

Canaccord comments that on a macro level, they believe “digital assets are biased higher in the medium term.” Specifically, Ethereum and Bitcoin which have seen the least volatility over recent months. As some of these asset prices have slowly rebounded, Canaccord believes this will have a more significant positive impact on miners than any other segment of the asset class.

On a company level, HIVE’s mining efficiency, “is supported by a modern mining fleet and diversification into mining ETH.” While most recently, the company received the first Intel ASIC explicitly designed for bitcoin mining. On top of this, HIVE recently completed building a fourth facility at its New Brunswick site. These are all things that Canaccord highlights when saying that HIVE is currently executing on its plan.

Lastly, Canaccord believes that HIVE “checks several other boxes that we like,” which include things like 100% green energy, a business model that has optionality, and “a solid BTC HODL relative to market cap.” With all these, Canaccord expects HIVE to see multiple expansion as both the overall and crypto markets slowly start to rebound. They write, “we remain positive on Hive’s outlook.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Cambria Drills 17.95 g/t Gold Over 22 Metres At Premier Mine

Denarius Metals Increases Bid For Emerita Resources To $0.45 Per Share

Related News

Green Thumb Sees Consensus Estimate Fall To $49.89 After Q4 Earnings

Earlier this week, Green Thumb Industries (CSE: GTII) reported its fourth quarter financial results. The...

Thursday, March 3, 2022, 04:31:00 PM

Another Giant E&P Company Enters Bitcoin Mining Industry; Negative Margin Implications For Legacy Miners

Very uncharacteristically, Canadian Bitcoin mining stocks, such as Bitfarms Ltd. (TSXV: BITF), Hut 8 Mining...

Sunday, January 3, 2021, 01:30:00 PM

Ascot Resources Sees BMO Lower Target To $1.25 Following Construction Delays

On June 23rd, Ascot Resources (TSX: AOT) provided investors with a series of updates. In...

Sunday, June 26, 2022, 11:07:00 AM

Analysts Anticipate United Airlines Q2 Revenues Of $5.4 Billion

United Airlines (NASDAQ: UAL) will be reporting their second quarter financial results on July 20th...

Tuesday, July 20, 2021, 03:36:00 PM

WeedMD: Canaccord Initiates Coverage With $0.60 Price Target

Yesterday morning, Canaccord Genuity initiated coverage on WeedMD Inc (TSXV: WMD) with a C$0.60 12-month...

Thursday, March 25, 2021, 11:47:00 AM